Intriguingly, TAMs can modulate therapy resistance by upregulating CDA in cancer cells [160] and by releasing pyrimidine nucleoside deoxycytidine that competes with GEM and lowers its active dose [144] (Figure 2). The gene discussed is CDA; the disease is cancer.